|Bid||6.40 x 4000|
|Ask||6.47 x 4000|
|Day's range||5.89 - 6.50|
|52-week range||3.71 - 18.98|
|Beta (5Y monthly)||3.24|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The company said medical distribution from the Aurora Polaris facility that is being shut down will move to an adjacent factory called Aurora Sky, while manufacturing will move to its Aurora River factory in Ontario. "We aspire to be a leaner, more agile organization that keeps pace with our competition and is on a path to profitability," a spokesperson for the company said in an email statement.
As of 11:05 a.m. EDT, shares of Canopy Growth (NASDAQ: CGC) have fallen 5.8%, Tilray (NASDAQ: TLRY) is down 6%, and Aurora Cannabis (NASDAQ: ACB) is bringing up the rear with a 6.3% decline. The past several days have seen a series of cuts to marijuana stock price targets among Wall Street analysts, you see, in advance of Aurora Cannabis' upcoming fiscal fourth-quarter 2021 earnings report (due out tomorrow). The bad news began back on Thursday, when Roth Capital cut its price target on Tilray in half, to $12 a share, commenting that management's sales projections for fiscal 2024 were too "hopeful" to be true.
After the markets close Sept. 21, Aurora Cannabis (NASDAQ: ACB) will release results for its fiscal fourth quarter, which ended June 30. The troubled Canadian pot company's stock is already down by about 20% year to date -- a sharp contrast to the sector benchmark Horizons Marijuana Life Sciences ETF, which is up 5% -- and the upcoming report could be pivotal in determining whether the share price gets out of the red for 2021. Investors aren't expecting to see Aurora turn a profit in the final quarter of its fiscal year, but there are other ways that the company can show it is making progress.